Share
Two recent papers touted the benefits of having an endocrine hospitalist-led Inpatient Diabetes Management Service (IDMS) in a community hospital setting to reduce the rates of both hypoglycemia and hyperglycemia, length of stay, and even hospital costs. Endocrine News gets a firsthand look at a community hospital’s use of an IDMS from both endocrinologists and...
Share
There were no significant differences in health outcomes for pregnant women who were diagnosed with gestational diabetes or their babies using two different clinically recommended screening methods, according to results from a large-scale clinical trial conducted by Kaiser Permanente researchers and published in The New England Journal of Medicine. Although there is evidence that treating...
Share
Factors other than how much weight a woman gains during pregnancy may contribute to metabolic complications such as gestational diabetes (GDM), according to a paper recently published in Journal of the Endocrine Society. Researchers led by Fernanda L. Alvarado, MD, of the Mother Infant Research Institute at Tufts Medical Center in Boston, Mass., point out...
Share
[Editor’s note: This post has been updated to clarify that the meta-analysis published in Diabetologia and the Phase IIb trial were separate studies.] Earlier this fall, Phase IIb topline results of the DIAGNODE-2 trial demonstrated a potential type 1 diabetes vaccine GAD-alum — an immunomodulating antigen-specific therapy – had a highly significant and clinically relevant...
Share
For the sixth year running, Endocrine News talks to editors from Endocrine Society publications to get the scoop on the top endocrine discoveries of 2020. In this first installment, we talk to Endocrinology editors about what they think this year’s most significant studies were that will impact endocrine science for years to come. Despite the...
Share
Variants in genes that mediate fibroblast growth factor 21 – a hormone secreted by the liver that acts to regulate the body’s response to starvation – have for the first time been linked to severe insulin resistance, according to a paper recently published in the Journal of the Endocrine Society. Researchers led by Stephen Stone,...
Share
First study to utilize CGM data with FDA-cleared, cloud-based titration software suggests significantly improved outcomes for patients while optimizing clinical resources This past summer, Glytec published the first proof-of-concept study that combines FDA-cleared remote insulin titration software and data from continuous glucose monitoring (CGM) systems. Results of the study, presented at the American Diabetes Association’s...
Share
A clinical trial investigating a possible novel treatment of early-onset type 1 diabetes last month met the primary endpoint assessing the safety and tolerability of a new class of microbe-based therapeutic agents. Precigen ActoBio is evaluating this therapy — AG019 ActoBiotics — as a monotherapy and in combination with teplizumab. AG019 is formulated as an...
